ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $11,000 | -90.0% | 149 | -88.6% | 0.00% | -90.9% |
| Q4 2021 | $110,000 | -53.4% | 1,307 | -50.2% | 0.01% | -8.3% |
| Q3 2021 | $236,000 | +47.5% | 2,623 | +56.1% | 0.01% | +71.4% |
| Q2 2021 | $160,000 | -28.9% | 1,680 | -15.1% | 0.01% | -41.7% |
| Q1 2021 | $225,000 | -11.4% | 1,979 | -36.1% | 0.01% | -25.0% |
| Q3 2020 | $254,000 | +229.9% | 3,098 | +218.4% | 0.02% | +220.0% |
| Q2 2020 | $77,000 | +1440.0% | 973 | +826.7% | 0.01% | – |
| Q1 2020 | $5,000 | 0.0% | 105 | -15.3% | 0.00% | – |
| Q3 2019 | $5,000 | -87.8% | 124 | -79.3% | 0.00% | -100.0% |
| Q1 2019 | $41,000 | +583.3% | 598 | +321.1% | 0.00% | +200.0% |
| Q4 2018 | $6,000 | +100.0% | 142 | +91.9% | 0.00% | – |
| Q4 2017 | $3,000 | -50.0% | 74 | -25.3% | 0.00% | -100.0% |
| Q2 2017 | $6,000 | – | 99 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |